Engineered T cells directed at tumors with defined allelic loss

• Published in: Molecular immunology 2020-12, Vol.128, p.298-310
• Main Authors: Hamburger, Agnes E., DiAndreth, Breanna, Cui, Jiajia, Daris, Mark E., Munguia, Melanie L., Deshmukh, Kiran, Mock, Jee-Young, Asuelime, Grace E., Lim, Emily D., Kreke, Michelle R., Tokatlian, Talar, Kamb, Alexander
• Format: Article
• Language: English
• Subjects: Alleles; AND NOT logic; Animals; Antigens, CD19 - immunology; CAR; Cell Line, Tumor; Cell therapy; Female; HLA-A Antigens - immunology; Humans; Immuno-oncology; Jurkat Cells; Ligands; LOH; Loss of Heterozygosity - immunology; Mice; Mice, Inbred NOD; Neoplasms - immunology; T-Lymphocytes - immunology; TCR
• ISSN: 0161-5890; 1872-9142
• DOI: 10.1016/j.molimm.2020.09.012

[Display omitted] •A synthetic signal integration system taps into a large, new class of cancer targets.•Takes advantage of common loss of heterozygosity at specific loci, such as HLA.•Works robustly in Jurkat and primary T cells, and a mouse xenograft cancer model.•The system, with minimal optimization, meets several requirements of a cell therapy. We describe an approach to cancer therapy based on exploitation of common losses of genetic material in tumor cells (loss of heterozygosity) (Basilion et al., 1999; Beroukhim et al., 2010). This therapeutic concept addresses the fundamental problem of discrimination between tumor and normal cells and can be applied in principle to the large majority of tumors. It utilizes modular activator/blocker elements that integrate signals related to the presence and absence of ligands displayed on the cell surface (Fedorov et al., 2013). We show that the targeting system works robustly in vitro and in a mouse cancer model where absence of the HLA-A*02 allele releases a brake on engineered T cells activated by the CD19 surface antigen. This therapeutic approach potentially opens a route toward a large, new source of cancer targets.